Table 1.
Study characteristics and screening methods used to select candidates for TA
| Author | Year | Study country | Study period | Study design | Study inclusion characteristics for screening | Screening methods used to determine eligibility for TA |
| Banerjee et al9 | 2020 | India | February 2016–July 2017 | Prospective randomised trial | 30–60 years old, non-pregnant, previously unscreened women | VIA or HPV |
| Campbell et al23 | 2016 | Malawi | October 2013–March 2015 | Quality improvement | 16–86 years old, non-pregnant | VIA |
| Chigbu et al18 | 2020 | Nigeria | 2014–2018 | Prospective analytical/comparative study | Women | VIA and colposcopy |
| Duan et al28 | 2021 | China | May 2017–May 2018 | Prospective randomised trial | 20–49 years old, non-pregnant, negative endocervical curettage and no vaginal lesions, women were excluded if they had a history of invasive cervical treatment or had been previously vaccinated for HPV | Cytology or HPV, and colposcopy and histology |
| Eakin et al24 | 2018 | Cameroon | Single day | Implementation pilot | 25+ years old, non-pregnant, no evidence of infection, no previous hysterectomy, university-based population (students, faculty and staff) |
VIA or VILI |
| Fokom Domgue et al25 | 2020 | Cameroon | April 2016–ongoing | Implementation | 30–65 years old, non-pregnant women | HPV |
| Joshi et al10 | 2013 | India | September 2010–November 2011 | Cross-sectional | 21–60 years old, HIV-positive women (with serological evidence), no debilitating illness as assessed by the study clinician, intact uterus with no prolapse, no previous history of cervical neoplasia | Colposcopy |
| Joshi et al26 | 2015 | India | October 2012–February 2013 | Cross-sectional | 18–60 years old, female sex workers, non-pregnant, with no history of prolapse, no history of treatment for cervical neoplasia, and having an intact uterus | Colposcopy |
| Mungo et al19 | 2020 | Kenya | August 2019–Feb 2020 | Prospective cohort | 25–65 years old, HIV-positive, non-pregnant, no history of cervical cancer or precancer treatment | HPV |
| Naud et al22 | 2016 | Brazil | March 2012–October 2019 | Retrospective cohort | Not reported | Colposcopy and histology |
| Pinder et al11 | 2020 | Zambia | August 2017–January 2019 | Prospective, unblinded, randomised control trial, pilot | 25+ years old, non-pregnant, no previous treatment to the cervix for any reason, no genital tract cancer | VIA |
| Sandoval et al20 | 2019 | Honduras | Over a period of 5 months | – | 30–49 years old, non-pregnant, pre-menopausal women | HPV and VIA |
| Viviano et al21 | 2017 | Cameroon | July 2015–December 2015 | Prospective study | 30–49 years old, non-pregnant, no previous total hysterectomy | HPV (self-sampling), and VIA for some |
| Zhao et al12 | 2021 | China | April 2017–April 2019 | – | 20–65 years old, non-pregnant, no history of treatment for cervical lesions | HPV (self-sampling), colposcopy |
| Zhao et al27 | 2020 | China | June 2017–unknown | Prospective study | 30–65 years old, non-pregnant, intact cervix and ever sexually active, excluded those with debilitating disease or with history of treatment for premalignant or malignant cervical lesions | HPV (self-sampling), colposcopy |
HPV, human papillomavirus; TA, thermal ablation; VIA, visual inspection with acetic acid; VILI, visual inspection with Lugol’s iodine.